Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

Zacks Equity Research

2 July 2024 at 10:40 am·4-min read

Neuronetics, Inc. STIM recently announced the nationwide launch of the Better Me Provider (BMP) program. The BMP program will be a part of the company’s NeuroStar product line. The providers participating in the program are expected to maintain correct standards, developed in collaboration with a network of transcranial magnetic stimulation (TMS) medical experts.

The latest development will help Neuronetics meet new standards and improve treatment accessibility within the mental health industry.

About BMP Program

Better Me Provider Program is an extensive commercial initiative to support practices committed to meeting patient care and responsiveness standards. These standards are developed in collaboration with TMS medical experts, ensuring prompt response times by a dedicated NeuroStar coordinator, who advises patients about the benefits of the entire course of NeuroStar treatment, along with optimizing websites and social media content to educate patients. It is designed to help people with major depressive disorder (MDD), obsessive-compulsive disorder, and anxious depression.

More on the News

In the initial days of the trial, the BMP program showed success by significantly increasing provider efficiency and responsiveness.

The trial result validated that the BMP program significantly accelerated patient engagement by swiftly addressing interested patients. Through advanced training of the providers and improved response time, the company is expecting to treat more patients in need of life-changing therapy.

Image Source: Zacks Investment Research

Industry Prospects

Per a report from Skyquest, the global Mental Health market was valued at $399.6 billion in 2022 and is expected to grow $544.6 billion by 2031, at a CAGR of 3.5% during the period. The primary factors influencing the global market include the increasing prevalence of mental health disorders worldwide and advancements in technology and research, which have led to the development of innovative treatment options. The growing awareness and acceptance of mental health issues also contribute to the market's growth.

Looking at the market potential, Neuronetics’ latest development is thoughtful and well-timed.

Other Notable Developments

Earlier this year, Neuronetics announced the FDA clearance of NeuroStar Advanced Therapy for usage as a supplement to treat MDD in adolescents aged between 15 years and 21 years. NeuroStar is the first and only FDA-approved transcranial magnetic stimulation treatment available for this age group.

In March 2024, Neuronetics entered into an expanded commercial partnership with Transformations Care Network (TCN), a mental health care provider. The company will supply new TMS equipment to TCN. This partnership marks a significant advancement in the field of mental health treatment, particularly for patients suffering from MDD and treatment-resistant depression.

Price Performance

In the past year, STIM’s shares have lost 21.2% against the industry’s 3.1% growth.

Zacks Rank and Key Picks

Neuronetics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, The Joint Corp. JYNT and Medpace Holdings MEDP. While Hims & Hers and The Joint sport a Zacks Rank #1 (Strong Buy) each, Medpace Holdings carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hims & Hers Heath stock has surged 135.1% in the past year. Estimates for the company’s 2024 earnings have moved north by 5.6% to 19 cents per share in the past 30 days.

HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.

Estimates for The Joint’s 2024 earnings per share (EPS) have remained constant at 21 cents in the past 30 days. Shares of JYNT have surged 37.4% year to date against the industry’s 3.6% decline.

In the last reported quarter, JYNT delivered an earnings surprise of 300%. It has a trailing four-quarter average earnings surprise of 18.75%.

Estimates for Medpace’s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have surged 70.4% in the past year compared with the industry’s 5.3% growth.

MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Joint Corp. (JYNT) : Free Stock Analysis Report

Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report

Neuronetics, Inc. (STIM) : Free Stock Analysis Report

Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The Independent
Nearly 500 people hospitalised in Japan after taking red yeast supplements
Kobayashi Pharmaceutical’s beni koji dietary supplements have been linked to 175 deaths so far
INSIDER
Russia's war-driven economy is so hot that the World Bank upgraded it to a 'high-income country'
Russia's trade rebounded by nearly 7% last year, while activities in the financial sector and construction grew by 6.6% and 3.6% respectively.
Bloomberg
6 family office funds tied to Singapore launder case got tax breaks
Six single family office funds linked to a S$3 billion money laundering case in Singapore have received tax incentives from the Monetary Authority of Singapore.
The Wrap
Paramount, Skydance Merger Is on Again in $2.4 Billion Deal
But NAI's controlling shareholder Shari Redstone might be setting off a bidding war ahead of Sun Valley The post Paramount, Skydance Merger Is on Again in $2.4 Billion Deal appeared first on TheWrap.
The Guardian
Coffee, eggs and white rice linked to higher levels of PFAS in human body
US study that researchers say highlights chemicals’ ubiquity also shows PFAS association with seafood and red meat
NextShark
Chinese researchers discover gene that protects Asians from obesity
Researchers at Fudan University in China have identified a specific gene variant that appears to protect people in southern China and Southeast Asia from obesity. The study, published in the Journal of Genetics and Genomics last month, involved the analyses of 16 basal mitochondrial DNA (mtDNA) haplogroups, genetic families that trace back to a common ancestor.
The Telegraph
Rheumatoid arthritis forced me to change my diet – and now I’m pain free
I can’t remember a time in my life when there hasn’t been pain somewhere in my body. It came to dominate much of my adult life. If somebody hasn’t been in constant pain, it’s hard to describe it to them. You’re masking the whole time, and everything is so much more difficult. The mornings were the worst for me as the throbbing and aching sensations would set in when I was lying still. The day it took me 45 minutes just to get out of bed because of the agony I was in, I knew something had to chan
Malay Mail
A-G’s report: Mara Inc’s inefficient operations lead to RM286m loss
KUALA LUMPUR, July 4 — Government-linked Mara Inc has incurred RM286.30 million in losses due to inefficient business op...
Yahoo Finance
Fed officials touted 'modest further progress' on inflation at last meeting: Minutes
Fed officials offered encouragement about the path of inflation while meeting in June, but they made it clear they didn’t expect to lower rates until they saw more evidence of a downward trend.
Zacks
BP CEO Halts Offshore Wind Projects, Enacts Hiring Freeze
BP's new CEO Murray Auchincloss has implemented a hiring freeze and paused new offshore wind projects, shifting the company's focus to oil and gas to address investor concerns over its energy transition strategy.
Zacks
Shell (SHEL) Hits Pause on Major Biofuels Plant in Europe
Shell (SHEL) remains committed to achieving its net-zero emissions target by 2050 despite abandoning several renewable projects to focus on its more profitable ventures, primarily in oil and gas.
Tom's Guide
Forget weights — I tried this Pilates roll-up exercise that strengthens your core and boosts your posture
You don't need equipment to build a stronger core and boost spine mobility. Here are the benefits of the Pilates roll-up exercise, and how it can help your body.
The Independent
Teen severs his spinal cord after jumping into pool to avoid wasp: ‘This is a long road’
Doctors do not believe that the teen will regain the ability to use his hands or feet
Zacks
Mondelez (MDLZ) Navigates Hurdles Through Portfolio Strength
Mondelez's (MDLZ) focus on core categories and portfolio strength place it well in a challenging and dynamic operating environment.
Zacks
SLB and TotalEnergies Ink 10-Year Digital Solutions Partnership
SLB and TotalEnergies enter into a 10-year collaboration to co-develop scalable digital solutions, focusing on enhancing energy resource access and efficiency through advanced AI technologies.
Evening Standard
LAS introduces 'cuddle pockets' for grieving parents to take miscarried babies to hospital
Knitted pouches will allow bereaved families to hold baby after birth and in ambulance
Yahoo Finance Video
Fed won't hit 2% target until 2026: Economist
With somewhat cooling inflation and stagnant labor market growth, conversations about whether the Federal Reserve's interest rate cut timing persist. Interactive Brokers senior economist José Torres joins Market Domination to give insight into the labor market, the broader stock market, and the Fed's future policy decisions. "I think we're going to hit the Fed's 2% target somewhere in 2026. Fed Chair Powell was asked about it; he didn't think that we would hit it this year or next year. In fact, when we consider the disinflation that occurred last year in the second half, now those base effects become unfavorable into the second half of this year. So we're going to actually see core PCE start to tick higher. And if you look at the dots of summary of economic projections from the Fed, they're expecting core PCE to finish the year around 2.8," Torres tells Yahoo Finance. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino
AFP News
London stocks, pound climb as Britons vote
London's stock market and the pound advanced versus the dollar Thursday as Britons voted in a general election expected to be won by the centre-left and main opposition Labour party."Today's UK election looks unlikely to cause too many shockwaves given just how resounding the Labour party victory is expected to be, with markets feeling optimistic over the potential change at Downing Street," said Scope Markets analyst Joshua Mahony.
The Telegraph
US market exceptionalism is approaching its dramatic denouement
The investment focus naturally shifts to the US on Independence Day but more so than ever this year as the completion of elections here on Thursday and in France at the weekend moves the political spotlight across the Atlantic too.
The Telegraph
What watching England play football does to your body
Watching England play in a major tournament is an emotional rollercoaster with moments of joy, despair and high stress arriving in quick succession. But have you ever wondered what the impact of putting yourself through such highs and lows is? We decided to put it to the test by finding out exactly what my body went through while watching England’s 2-1 win over Slovakia – and probably yours, too.